232 related articles for article (PubMed ID: 36542815)
1. Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas.
Mutter JA; Alig SK; Esfahani MS; Lauer EM; Mitschke J; Kurtz DM; Kühn J; Bleul S; Olsen M; Liu CL; Jin MC; Macaulay CW; Neidert N; Volk T; Eisenblaetter M; Rauer S; Heiland DH; Finke J; Duyster J; Wehrle J; Prinz M; Illerhaus G; Reinacher PC; Schorb E; Diehn M; Alizadeh AA; Scherer F
J Clin Oncol; 2023 Mar; 41(9):1684-1694. PubMed ID: 36542815
[TBL] [Abstract][Full Text] [Related]
2. Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA.
Heger JM; Mattlener J; Schneider J; Gödel P; Sieg N; Ullrich F; Lewis R; Bucaciuc-Mracica T; Schwarz RF; Rueß D; Ruge MI; Montesinos-Rongen M; Deckert M; Blau T; Kutsch N; Balke-Want H; Weiss J; Becker K; Reinhardt HC; Hallek M; Borchmann P; von Tresckow B; Borchmann S
Blood; 2024 Feb; 143(6):522-534. PubMed ID: 37946299
[TBL] [Abstract][Full Text] [Related]
3. Clinical applications of circulating tumor DNA in central nervous system lymphoma.
Foerster AK; Lauer EM; Scherer F
Semin Hematol; 2023 Jul; 60(3):150-156. PubMed ID: 37442670
[TBL] [Abstract][Full Text] [Related]
4. Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028).
Li M; Chen J; Zhang B; Yu J; Wang N; Li D; Shao Y; Zhu D; Liang C; Ma Y; Ou Q; Hou X; Chen L
BMC Med; 2022 Nov; 20(1):398. PubMed ID: 36372873
[TBL] [Abstract][Full Text] [Related]
5. Circulating Tumor DNA Dynamics as Prognostic Markers in Locally Advanced and Metastatic Esophageal Squamous Cell Carcinoma.
Ng HY; Ko JMY; Lam KO; Kwong DLW; Lo AWI; Wong IYH; Wong CLY; Chan SY; Chan KK; Law TT; Dai W; Fong HCH; Choy FSF; Lo CK; Chen C; Law SYK; Lung ML
JAMA Surg; 2023 Nov; 158(11):1141-1150. PubMed ID: 37728901
[TBL] [Abstract][Full Text] [Related]
6. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.
Bernard V; Kim DU; San Lucas FA; Castillo J; Allenson K; Mulu FC; Stephens BM; Huang J; Semaan A; Guerrero PA; Kamyabi N; Zhao J; Hurd MW; Koay EJ; Taniguchi CM; Herman JM; Javle M; Wolff R; Katz M; Varadhachary G; Maitra A; Alvarez HA
Gastroenterology; 2019 Jan; 156(1):108-118.e4. PubMed ID: 30240661
[TBL] [Abstract][Full Text] [Related]
7. Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy.
Li M; Mi L; Wang C; Wang X; Zhu J; Qi F; Yu H; Ye Y; Wang D; Cao J; Hu D; Yang Q; Zhao D; Ma T; Song Y; Zhu J
BMC Med; 2022 Oct; 20(1):369. PubMed ID: 36280874
[TBL] [Abstract][Full Text] [Related]
8. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer.
Yang J; Gong Y; Lam VK; Shi Y; Guan Y; Zhang Y; Ji L; Chen Y; Zhao Y; Qian F; Chen J; Li P; Zhang F; Wang J; Zhang X; Yang L; Kopetz S; Futreal PA; Zhang J; Yi X; Xia X; Yu P
Cell Death Dis; 2020 May; 11(5):346. PubMed ID: 32393783
[TBL] [Abstract][Full Text] [Related]
9. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer.
Tarazona N; Gimeno-Valiente F; Gambardella V; Zuñiga S; Rentero-Garrido P; Huerta M; Roselló S; Martinez-Ciarpaglini C; Carbonell-Asins JA; Carrasco F; Ferrer-Martínez A; Bruixola G; Fleitas T; Martín J; Tébar-Martínez R; Moro D; Castillo J; Espí A; Roda D; Cervantes A
Ann Oncol; 2019 Nov; 30(11):1804-1812. PubMed ID: 31562764
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases.
Baumgartner JM; Riviere P; Lanman RB; Kelly KJ; Veerapong J; Lowy AM; Kurzrock R
Ann Surg Oncol; 2020 Sep; 27(9):3259-3267. PubMed ID: 32767050
[TBL] [Abstract][Full Text] [Related]
11. Improved early outcome prediction by MRI-based 3D tumor volume assessment in patients with CNS lymphomas.
Lauer EM; Riegler E; Mutter JA; Alig SK; Bleul S; Kuehn J; Ranganathan L; Klingler C; Demerath T; Würtemberger U; Rau A; Weiß J; Eisenblaetter M; Bamberg F; Prinz M; Finke J; Duyster J; Illerhaus G; Diehn M; Alizadeh AA; Schorb E; Reinacher PC; Scherer F
Neuro Oncol; 2024 Feb; 26(2):374-386. PubMed ID: 37713267
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis.
Jones RP; Pugh SA; Graham J; Primrose JN; Barriuso J
Eur J Cancer; 2021 Feb; 144():368-381. PubMed ID: 33422803
[TBL] [Abstract][Full Text] [Related]
13. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
[TBL] [Abstract][Full Text] [Related]
14. Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA.
Liu LP; Zong SY; Zhang AL; Ren YY; Qi BQ; Chang LX; Yang WY; Chen XJ; Chen YM; Zhang L; Zou Y; Guo Y; Zhang YC; Ruan M; Zhu XF
Clin Cancer Res; 2024 Mar; 30(6):1143-1151. PubMed ID: 38170574
[TBL] [Abstract][Full Text] [Related]
15. Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer.
Waldeck S; Mitschke J; Wiesemann S; Rassner M; Andrieux G; Deuter M; Mutter J; Lüchtenborg AM; Kottmann D; Titze L; Zeisel C; Jolic M; Philipp U; Lassmann S; Bronsert P; Greil C; Rawluk J; Becker H; Isbell L; Müller A; Doostkam S; Passlick B; Börries M; Duyster J; Wehrle J; Scherer F; von Bubnoff N
Mol Oncol; 2022 Jan; 16(2):527-537. PubMed ID: 34653314
[TBL] [Abstract][Full Text] [Related]
16. Initial Report: Personalized Circulating Tumor DNA and Survival in Patients with Resectable Pancreatic Cancer.
Eckhoff AM; Kanu E; Fletcher A; Bao M; Aushev VN; Spickard E; Nussbaum DP; Allen PJ
Ann Surg Oncol; 2024 Mar; 31(3):1444-1446. PubMed ID: 38170407
[TBL] [Abstract][Full Text] [Related]
17. Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas.
Bobillo S; Crespo M; Escudero L; Mayor R; Raheja P; Carpio C; Rubio-Perez C; Tazón-Vega B; Palacio C; Carabia J; Jiménez I; Nieto JC; Montoro J; Martínez-Ricarte F; Castellvi J; Simó M; Puigdefàbregas L; Abrisqueta P; Bosch F; Seoane J
Haematologica; 2021 Feb; 106(2):513-521. PubMed ID: 32079701
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumor DNA predicts outcome in metastatic gastroesophageal cancer.
van Velzen MJM; Creemers A; van den Ende T; Schokker S; Krausz S; Reinten RJ; Dijk F; van Noesel CJM; Halfwerk H; Meijer SL; Mearadji B; Derks S; Bijlsma MF; van Laarhoven HWM
Gastric Cancer; 2022 Sep; 25(5):906-915. PubMed ID: 35763187
[TBL] [Abstract][Full Text] [Related]
19. Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers.
Bellone S; McNamara B; Mutlu L; Demirkiran C; Hartwich TMP; Harold J; Yang-Hartwich Y; Siegel ER; Santin AD
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240216
[TBL] [Abstract][Full Text] [Related]
20. Serial Circulating Tumor DNA Mutational Status in Patients with KRAS-Mutant Metastatic Colorectal Cancer from the Phase 3 AIO KRK0207 Trial.
Lueong SS; Herbst A; Liffers ST; Bielefeld N; Horn PA; Tannapfel A; Reinacher-Schick A; Hinke A; Hegewisch-Becker S; Kolligs FT; Siveke JT
Clin Chem; 2020 Dec; 66(12):1510-1520. PubMed ID: 33257977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
